Research programme: immunotherapeutic vaccines - Scancell

Drug Profile

Research programme: immunotherapeutic vaccines - Scancell

Alternative Names: Modi-1; PAP vaccine - Scancell; PAP-114; SCIB-2; SCMod 1

Latest Information Update: 29 Sep 2016

Price : $50

At a glance

  • Originator Scancell
  • Developer Karolinska Institute; Scancell
  • Class Cancer vaccines; DNA vaccines; Protein-vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Rheumatoid arthritis
  • Discontinued Infections

Most Recent Events

  • 16 Sep 2016 Scancell and the Addario Lung Cancer Medical Institute plan a phase I/II trial for SCIB 2 in Non-small cell lung cancer (Combination therapy)
  • 13 Jul 2016 Scancell plans a clinical trial for Solid tumours
  • 11 Mar 2016 Early research in Rheumatoid arthritis in Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top